Source: yahoo_news
Source ID: yahoo:de03e240e5b6ffc72195993e3534a929:OCS
URL: https://finance.yahoo.com/healthcare/articles/oculis-reports-q3-2026-financial-210500756.html?.tsrc=rss
Symbol: (OCS)
Published: 2026-11-03 16:05:00 EST
Time precision: minute
Title: Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

Licaminlimab (PREDICT-1): Patient randomization is now complete in the registrational symptoms trial evaluating Licaminlimab for TNFR1-mediated dry eye disease (DED). Topline results are anticipated around year-end 2026.Privosegtor (PIONEER-1): Advancing global registrational trial in optic neuritis (ON), reinforced by new biomarker data supporting its neuroprotective potential. IND clearance to initiate trials in acute multiple sclerosis (MS) relapses is expected in Q4 2026.R&D Day scheduled fo